Simple Summary Ovarian cancer is a lethal disease in women with a 10-year survival rate
of< 40% worldwide. A key molecular alteration in ovarian cancer is the aberrant …

As a kind of gynecological tumor, ovarian cancer is not as common as cervical cancer and
breast cancer, but its malignant degree is higher. Despite the increasingly mature treatment …

Background Celastrol, a pentacyclic triterpenoid quinonemethide isolated from several spp.
of Celastraceae family, exhibits anti-inflammatory activities in a variety of diseases including …

One major characteristic of tumor cells is the aberrant activation of epigenetic regulatory
elements, which remodel the tumor transcriptome and ultimately promote cancer …

Small cell lung cancer (SCLC) continues to cause poor clinical outcomes due to limited
advances in sustained treatments for rapid cancer cell proliferation and progression. The …

Inducing homologous-recombination (HR) deficiency is an effective strategy to broaden the
indications of PARP inhibitors in the treatment of triple-negative breast cancer (TNBC) …

Although numerous studies indicate that inhibition of USP7 suppresses tumor growth by
activating p53, the precise mechanism by which USP7 contributes to tumor growth through …

Abstract Poly (ADP-ribose) polymerase (PARP) inhibitors offer a significant clinical benefit
for triple-negative breast cancers (TNBCs) with BRCA1/2 mutation. However, the narrow …

We have earlier reported anticancer activity in Withaferin A (Wi-A), a withanolide derived
from Ashwagandha (Withania somnifera) and caffeic acid phenethyl ester (CAPE), an active …

The FOXM1 transcription factor is an oncoprotein and a top biomarker of poor prognosis in
human cancer. Overexpression and activation of FOXM1 is frequent in high-grade serous …